Latest News
AGC Biologics to manufacture AAVantgarde's dual-vector gene therapies for inherited retinal diseases
21 November 2025 - AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), on Friday announced a manufacturing agreement with clinical-stage biotechnology company AAVantgarde to produce two dual-vector ge...
Flagship Pioneering announces new agreements with ProFound Therapeutics and Quotient Therapeutics under GSK collaboration
21 November 2025 - Flagship Pioneering, a scientific innovation engine for transformative platforms and products, announced on Thursday that ProFound Therapeutics and Quotient Therapeutics have entered into feasibility agreements with biopharmaceutic...
Abbott agrees to acquire Exact Sciences
21 November 2025 - US-based global healthcare company Abbott (NYSE:ABT) announced on Thursday that it has signed a definitive agreement to acquire molecular diagnostics company Exact Sciences (NASDAQ:EXAS), allowing Abbott to enter and lead in fast-g...
HitGen signs new funding agreement with Gates Foundation
21 November 2025 - HitGen Inc (SSE:688222), a China-based drug discovery research company, announced on Thursday that it has signed a new agreement with the Gates Foundation, a US-based nonprofit fighting poverty, disease, and inequity around the wor...
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
20 November 2025 - Biopharmaceutical company Avidity Biosciences Inc (Nasdaq:RNA) announced on Wednesday its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrop...